We are live on ! Find out more
CUE icon

Cue Biopharma
CUE

97 hedge funds and large institutions have $241M invested in Cue Biopharma in 2020 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 40 increasing their positions, 22 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

86% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 7

82% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 22

5% more funds holding

Funds holding: 92 → 97 (+5)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.08% less ownership

Funds ownership: 2.21% → 2.13% (-0.08%)

17% less capital invested

Capital invested by funds: $291M → $241M (-$49.8M)

87% less call options, than puts

Call options by funds: $359K | Put options by funds: $2.72M

Holders
97
Holders Change
+5
Holders Change %
+5.43%
% of All Funds
1.72%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
13
Increased
40
Reduced
22
Closed
7
Calls
$359K
Puts
$2.72M
Net Calls
-$2.36M
Net Calls Change
-$2.55M

Top Buyers

Rank Fund Capital Flow
1
CA
Corriente Advisors
Texas
+$6.36M
2
Morgan Stanley
Morgan Stanley
New York
+$4.04M
3
PM
Prosight Management
Texas
+$2.62M
4
Millennium Management
Millennium Management
New York
+$2.42M
5
Goldman Sachs
Goldman Sachs
New York
+$2.34M

Top Sellers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
-$18.9M
2
WP
Woodline Partners
California
-$5.39M
3
Citadel Advisors
Citadel Advisors
Florida
-$2.53M
4
Federated Hermes
Federated Hermes
Pennsylvania
-$1.29M
5
BL
Bleichroeder LP
New York
-$999K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of Montreal
76
Bank of Montreal
Ontario, Canada
$66K +$43.2K +108 +169%
NFSG
77
Newbridge Financial Services Group
Florida
$50K – – –
Belvedere Trading
78
Belvedere Trading
Illinois
$45K +$47.5K +119 New
BNP Paribas Financial Markets
79
BNP Paribas Financial Markets
France
$43.9K -$44.4K -111 -49%
TRCT
80
Tower Research Capital (TRC)
New York
$42K +$29.2K +73 +187%
Zurich Cantonal Bank
81
Zurich Cantonal Bank
Switzerland
$41K – – –
AIP
82
Ameritas Investment Partners
Nebraska
$31K – – –
DOA
83
D'Orazio & Associates
Virginia
$25K – – –
Pacer Advisors
84
Pacer Advisors
Pennsylvania
$23K +$11.2K +28 +85%
SIAG
85
Signet Investment Advisory Group
Rhode Island
$19K +$20K +50 New
Canada Life
86
Canada Life
Manitoba, Canada
$15K – – –
Nisa Investment Advisors
87
Nisa Investment Advisors
Missouri
$13K +$13.2K +33 New
Macquarie Group
88
Macquarie Group
Australia
$10K – – –
QT
89
Quantbot Technologies
New York
$7K – – –
Federated Hermes
90
Federated Hermes
Pennsylvania
$5K -$1.29M -3,220 -100%
Royal Bank of Canada
91
Royal Bank of Canada
Ontario, Canada
$3K +$2K +5 +250%
PWPS
92
Pinnacle Wealth Planning Services
Ohio
$3K +$3.6K +9 New
Osaic Holdings
93
Osaic Holdings
Arizona
$2K – – –
PNC Financial Services Group
94
PNC Financial Services Group
Pennsylvania
$2K – – –
LWA
95
Lenox Wealth Advisors
New York
$1K – – –
PHK
96
Point72 Hong Kong
Hong Kong
$1K +$400 +1 New
AIG
97
American International Group
New York
$215 -$799 -2 -0.3%
Schroder Investment Management Group
98
Schroder Investment Management Group
United Kingdom
– -$821K -1,755 Closed
VIA
99
Vident Investment Advisory
Georgia
– -$743K -1,645 Closed
Jennison Associates
100
Jennison Associates
New York
– -$450K -996 Closed
1 2 3
4
5

CUE Hedge Fund Activity: Q4 2020 in Review

97 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q4 2020, worth a combined $241M — down 17% from $291M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new CUE positions and 7 closed out — a net gain of 6 holders — while 40 added to existing stakes and 22 trimmed.

The largest buyer was Corriente Advisors, adding an estimated $6.36M. The largest seller was Avoro Capital Advisors, cutting an estimated $18.9M.

  • 97 institutional investors held Cue Biopharma (CUE) as of Q4 2020, up from 92 in Q3 2020.
  • Funds reported $241M of Cue Biopharma stock for Q4 2020, down 17% quarter-over-quarter.
  • 13 funds opened new Cue Biopharma positions in Q4 2020 and 7 closed out, a net change of +6 holders.
  • The largest Cue Biopharma buyer in Q4 2020 was Corriente Advisors, an estimated $6.36M added.
  • The largest Cue Biopharma seller in Q4 2020 was Avoro Capital Advisors, an estimated $18.9M sold.

Based on aggregated 13F filings for Q4 2020.